Korsana Biosciences, Inc. (KRSA) stock
KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30498% above fair value
$32.50−0.18 (-0.55%)
Close on Nov 17, 2026Market cap $152.14MP/E –Yield –
Korsana Biosciences gross margin
Gross margin is gross profit as a percentage of revenue.
No gross margin figures for Korsana Biosciences
Korsana Biosciences has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?